I'm LongbridgeAI, I can summarize articles.Hypera reported a 15% year-over-year increase in Q2 2026 net income to R$490 million, with net revenue rising 8.5% to R$2.34 billion. Operating cash flow surged 85% to R$819.2 million, and gross margin expanded to 61.8%. Net debt decreased by R$397.6 million to R$5.9 billion. Additionally, Hypera announced a partnership with Astellas for fezolinetant treatments and received ANVISA approval for Semavy, entering the GLP-1 analog market.
- Hypera posted 2Q26 net revenue of R$ 2.34 billion, up 8.5% from 2Q25; net income from continuing operations rose 15% to R$ 490 million. * Operating cash flow jumped 85% to R$ 819.2 million, equal to 108.5% of EBITDA from continuing operations. * Gross margin widened 1.7 percentage points to 61.8%; EBITDA from continuing operations increased 4.1% to R$ 754.9 million. * Net debt fell to R$ 5.9 billion, down R$ 397.6 million from end-1Q26, reflecting stronger free cash flow of R$ 637.8 million. * Hypera announced an Astellas partnership for fezolinetant menopause treatments, while ANVISA approved Semavy, marking its entry into Brazil’s GLP-1 analog market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hypera SA published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here